

Transfer, validation and application of HPLC analytical method for simultaneous determination of paracetamol and diclofenac in tablets

Emile Tweni Baruti^{1,✉}, Jérémie Mbinze Kindenge², Issa Yakusu Issa³, Marguerite Borive Amani¹, Elodie Nsasi Bankiantima¹, Justin Ntokamunda Kadima^{1,5}, Roland Marini Djangeing'a^{1,4}.

1. Department of Pharmacy, Faculty of Medicine and Pharmacy, University of Kisangani, Democratic Republic of Congo;

2. Drug Analysis Laboratory, Department of Galenics and Drug Analysis, Faculty of Pharmaceutical Sciences, University of Kinshasa, Democratic Republic of Congo;

3. Department of Internal Medicine, Faculty of Medicine and Pharmacy, University of Kisangani

4. Laboratory of Pharmaceutical Analytical Chemistry, Faculty of Medicine, University of Liège, Belgium;

5. Department of Clinical Pharmacology, School of Medicine and Pharmacy, University of Rwanda, Rwanda.

✉Corresponding author: emiletweni@gmail.com

ABSTRACT

Various pharmaceutical preparations containing paracetamol in combination with other nonsteroidal anti-inflammatory drugs are produced for the treatment of postoperative pain management. A lack of selective analytical techniques makes it difficult to fully assay all incorporated active ingredients. An original HPLC method developed at the University of Liège for the assay of the paracetamol-diclofenac combination in tablets has been transferred and validated at the University of Kisangani for its application locally. The use of an Xbridge® column (C18, 100 x 4.6 mm/3.5µm) instead of Xbridge® (C18, 250 x 4.6mm/5µm) allowed to reduce the time of analysis from 60 min to 20 min, as well as the consumption of methanol in the mobile phase, while maintaining the efficiency and selectivity of the original method. After validation the method was applied for the analysis of two generics marketed in the city. The transferred method allows an appreciable saving in time and in the solvent economy to be applied in routine for quality control of generics in circulation.

Keywords: Paracetamol, Diclofenac, Tablets, HPLC, Geometric transfer, Validation, Optimization

INTRODUCTION

According to the WHO, 10% of drugs circulating in the world are of substandard quality, and the rate can reach proportions of 25 to 80% in Africa [1]. This requires the development of reliable analytical methods to ensure quality control [2, 3]. Increasingly, paracetamol is being formulated in combination with other nonsteroidal anti-inflammatory drugs (NSAIDs) for the treatment of postoperative pain [4]. The lack of physical methods of separating paracetamol in combination with diclofenac in compressed forms makes it difficult to fully dose these two active ingredients [5]. The United States Pharmacopeia (USP 39, 2016) and other monographs do not provide analytical methods for this combination. In 2012, Mbinze et al. [5] had developed and validated at the University of Liège in Belgium, an analytical method by high-performance liquid chromatography (HPLC) coupled to the UV detector for the simultaneous analysis of several combinations of NSAIDs under the same chromatographic conditions. The method received an Award at the 2012 HPLC International Congress in California, United States [6].

In the Democratic Republic of the Congo (RDC) and perhaps also in other African countries, the control laboratories are limited to dosing only paracetamol by default of separative methods. It is in this context that we tried to transfer, validate and apply the original method to the analysis of generics combining paracetamol and diclofenac with the objectives of reducing the analysis time and the consumption of methanol while maintaining efficiency and selectivity.

MATERIALS AND METHODS

MATERIALS

We used Diclofenac (SCR) (99.7%) from Sigma-Aldrich (Antwerp, Belgium), and Paracetamol SCR (99.5%) from Fagron N.V. (Waregem, Belgium) as reference standards and two generics DICDOL and VOLPA® containing each paracetamol 325 mg + diclofenac 50 mg. DICDOL presented as white-orange tablets scored in blister pack; batch 08; made on 07/2016; expire on 06/2019; manufactured by Renumed Pharmaceutical labs, Plot N° 15, DEWAN α Sons Udyog Nagar, Polgar, MH in INDIA. VOLPA® presented as white-orange tablets in blister packs; batch 00880; made on 07/2016; expire on 06/2019; manufactured by Syncom formulations (I) Ltd. Mumbai- 400093 in INDIA. The samples were purchased in a community drug dispensary in the

municipality of Makiso (Kisangani, DR Congo). The solvents consisted of HPLC grade methanol, hydrochloric acid (37%) from Merck (Darmstadt, Germany); ammonium formate (99%) from Alfa Aesar (Karlsruhe, Germany); ultra-pure quality water (18.2 MΩ.cm) purified with Milli-Q Plus 185 from Millipore (Billerica, Massachusetts-MA, USA) from Arauphar (Kinshasa, DR Congo).

PREPARATION OF SOLUTIONS

The standard stock solutions were prepared by accurately weighing 80 mg of SCR PC and 12.3mg of DICLO into a 20 ml volumetric flask. The drugs were dissolved in methanol, and the solution was diluted to volume with methanol-water milli-Q (50/50, v / v) to have 4000µg / ml. Successive dilutions were made from this stock solution with methanol-water milli-Q to prepare three solutions for calibration 240µg/ml, 160µg/mL, 80µg/mL. Also, successive dilutions were made from the stock solution with methanol-water milli-Q to have five standards solutions for validation 240µg/ml, 200µg/ml, 160µg/mL, 120µg/mL, 80µg/mL. The solution of 10 mM ammonium formate buffer was prepared by dissolving 0.16 g of ammonium formate in 200.0 mL water Milli-Q and adjust to pH 3.00 with 1N HCl.

INSTRUMENTATION AND CHROMATOGRAPHIC CONDITIONS

The protocol [5] required an HPLC chain Hitachi coupled to a UV-DAD 5430 detector (Antwerp, Belgium), using Chromaster software and Dell-type computer (Hangzhou, China), XBridge C18 column, 100 x 4.6 mm, (3.5 µm) Waters (Milford, Massachusetts - MA, USA). The adjustment of the pH values of the different buffer solutions was carried out using a HI 2211 PH / ORP pH meter (Hangzhou, China). We used the FV-220C GRAM analytical balance (Hangzhou, China), an ultrasonic bath CPX1800H-E VWR Hitachi. We used e-noval® software to process the validation results, and the HPLC calculator v3.0 software to perform the geometric transfer and fix the elution gradient. All solutions were filtered using PALL ACRODISC PSF GHP 0.45 µm brand filters before injection into HPLC.

METHOD VALIDATION[7]

SPECIFICITY

The specificity of this HPLC method was determined by complete separation of Paracetamol and Diclofenac without any interference of the excipient peak.

LINEARITY AND RANGE

For linearity, calibration curves were plotted over a concentration range of 80 to 240µg/mL for paracetamol and 12.3 to 37µg/mL for diclofenac. All measurements were repeated three times for each concentration, and the standard curve was constructed by plotting the peak areas of the analyte against the corresponding drug concentration. R-value ≥ 0.99 confirmed the good linearity of the method.

DETECTION AND QUANTIFICATION LIMITS

The limit of detection (LOD) and limit of quantitation (LOQ) were calculated using the linearity parameters. The values were calculated from the standard deviation (SD) of the response and the slope of the curve (S) using the equations: $LOD = 3.3(SD/S)$ and $LOQ = 10(SD/S)$.

PRECISION

The precision defined by repeatability and intermediate precision was evaluated by preparing three different sample solutions at low, medium, and high concentrations, which were freshly prepared and analyzed three times in 3 days. The precision of the method was expressed in RSD% and in Horwitz value. The relative standard deviation was evaluated by analyzing standard drug solutions within the calibration range.

ACCURACY

The accuracy was calculated as the difference between the theoretical amount added and the amount practically recovered. Recovery assays were performed in triplicate by the standard addition method at 50%, 100%, and 150%. The known amount of paracetamol and diclofenac standard was added to pre-analyzed samples and was subjected to the proposed method.

ANALYSIS OF THE COMMERCIAL FORMULATION

Aliquot of DCDOL and VOLPA powder exactly weighted close to 10 mg of paracetamol were introduced in a 10.0 mL and gauged with methanol. After filtration, dilutions were made to obtain 200 µg/mL of paracetamol.

Solutions of the generic samples on the market were analyzed accordingly to the developed method. The samples were extracted with methanol using ultrasound for 15 minutes, then filtered using a 0.45 µm PTFE filter.

RESULTS AND DISCUSSION

MODIFICATION OF THE ORIGINAL METHOD

Geometric transfer consisted of changing the geometry of the chromatography column in an analytical method. [Table 1](#) compares the operating conditions for modified and original methods. All conditions but column and mobile phase gradient were maintained. We replaced XBridge C18 (250 x 4,6 mm, 5µm) with XBridge C18 (100 x 4,6 mm, 3,5 µm).

Table 1 Operating conditions

Specifications	Original method	Transferred method
HPLC brand	VWR Hitachi	VWR Hitachi
Detector	UV-DAD 5430	UV-DAD 5430
Wave	220 nm	220 nm
Processor computer	Dell™ (Hangzhou)	Dell™ (Hangzhou)
Software	Chromaster de VWR Hitachi	Chromaster de VWR Hitachi
Column	XBridge C18 (250 x 4,6 mm, 5µm)	XBridge C18 (100 x 4,6 mm, 3,5 µm)
Temperature	30°C	30°C
Injection	20 µL	20 µL
Flow	1 mL/min	1 mL/min
Mobile phase	Methanol/Buffer pH 3	Methanol/Buffer pH 3
Gradient	0min : 15/85 20min :95/5 30min :95/5 31min :15/85 60min :15/85	0min : 15/85 7.22 min :95/5 11.22 min :95/5 11.64 min :15/85 20min :15/85

VALIDATION OF THE METHOD

The transferred method was validated using the same total error strategy that uses the accuracy profile as a decision tool. As shown in [Table 2](#) and [Figure 1](#), the fixed optimal conditions reduced the retention time of analysis from 60 min to 20 min, as well as the consumption of methanol used as eluent while maintaining efficiency and selectivity. The validation criteria concerned in this study are, selectivity, trueness, repeatability (CV% = 1.10-2.62) and intermediate precision (CV % = 1.10-2.46), accuracy, linearity (paracetamol = 2,984 + 0.980t; r2 = 0.996 and diclofenac = 0.37 + 0.989t, r2 = 0.994). Detection limits (0-240) and 12.3-37), limit of quantification (LOQ), dosing interval. The acceptance limit was set at ± 10% (i.e. 90 to 110%).

Table 2 System Suitability Parameters

System Suitability Parameters	Transferred method		Original method	
	PC	DC	PC	DC
Retention time	3.127	10.473	6.182	19.536
Relative Resolution time	0.299	0	0.316	1
LOQ range µg/ml	80- 240	12.3-37	80- 240	12.3-37
Target concentration µg/ml	160	24.64	160	24.64
Absolu biai µg/ml/	2.626	1.35		
Relatif biai %)	1.402	0.792		
Repeatability% RSD	1.774	1.466		
Intermediary precision% RSD	1.828	1.488		
Linearity Vxo	2.984	0.370		
Linearity Slope	0.980	0.989		
Linearity R	0.999	0.994		
Accuracy%	99.05–100.9.	99.05–100.9	99.05–100.9	99.05–100.9




Figure 1. Performances of the method

Legend: A= Gradient of methanol in the mobile phase; B=specificity of the original method; C= specificity of the transferred method; D= linearity profile; E= trueness profile;

To reduce this time we changed the column and using the HPLC calculator_version 2.1 software, we obtained a new elution gradient. Switching from one column to another with different characteristics sometimes influences retention time and chromatogram quality. This has been exploited in several scientific works, in particular when the modifications of the analytical conditions have affected the chromatographic behaviors, namely the retention time [6-9]. To compare the quality of the chromatograms, we used the relative retention time which is calculated from the last peak. Relative retention time = retention time of each peak / retention time of the last chromatographic peak. The results obtained show that the error or the difference between the relative retention times before and after the transfer is negligible, ie 0.017 minutes. The bias is slightly greater than that observed during the validation of the initial method, which is 1.01%. In all cases, that is to say before and after the geometric transfer, the accuracy remains good compared to the acceptance limits. The method has good reliability with a coefficient of variation of less than 2.46%. This CV is slightly higher than that of the previous method which is 1.21%. Accuracy takes into account total error, that is, systematic error and random error associated with the result. The transferred method is correct throughout the dosing range for both active substances. The same observation was made for the initial method [5]. We note in Table VI that the R2 of these two molecules are close to unit (1) which explains a good agreement between the concentrations introduced and the concentrations calculated in return.

ANALYSIS OF MARKETED FORMULATION

After demonstrating the reliability of the transferred method, we applied it to verify the quality of two brands marked locally. Beforehand, we performed visual inspection as well as pharmacotechnical pharmaceutical technology requirements by assessing the disintegration time, friability, and mass uniformity, according to the procedures of the British Pharmacopoeia Volume II 1993. The disintegration test was carried out at the laboratory departments of the Office Congolais de Contrôle de Kinshasa with Antou Paar Type DMA35 version 3 P/N 94138 Made in Austria and Crumbling with Friabilimetre Type TAR ERWEKA. The identification of the active ingredients in the sample was carried out by comparing the retention times of controls and those of the samples. Table 2 gives the system suitability parameters of the two generics tested.

Table 2 System Suitability Parameters

System Suitability Parameters	Dicdol®		Volpa®	
	Paracetamol	Diclofenac	Paracetamol	Diclofenac
Retention time	3.145	10.412	3.207	10.498
RRT	0.307	1	0.306	1
Gap between RT	0.034	0.164	0.096	0.086
Label content mg	325	50	325	50
Assay recovery %	102±0.26	102.2±1.68	100.6±0.85	102.0±1.17
Friability (n=10) % lost	2.805	2.684	2.805	2.684
Mean weight (n=10) mg	684.8	684.8	615.9	684.8

CONCLUSION

The use of a Xbridge® column (C18, 100 x 4.6 mm, 3.5µm dp) instead of Xbridge® (C18, 250 x 4.6mm, 5µm dp) improved the system suitability of the original method. This transferred method allows an appreciable saving in time and in the solvent economy to be applied in routine for quality control of generics in circulation.

REFERENCES

1. Daniela. Le point par l'OMS sur les médicaments de qualité inférieure et contrefaits- Bagozzi, Mai 2004.
2. Habyalimana V, Kalenda TN, Dispas A, Mbinze JK, J.L. Kadima N, Lebrun P, Hubert P, Marini RD. Méthodes chromatographiques génériques de criblage pour lutter contre les médicaments de qualité inférieure. *Spectra anal*, 298, 2014, 30-36.
3. Mbinze JK. développement de méthodes génériques pour le dosage des médicaments commercialisés sur le marché congolais : utilisation de méthodes séparatives et non séparatives, thèse de doctorat, Université de Liège, Belgique, 2015
4. Aweke Z, Seyoum F, Shitemaw T, Doba DN. Comparison of preemptive paracetamol, paracetamol-diclofenac & paracetamol-tramadol combination on postoperative pain after elective abdominal surgery under general anesthesia, Ethiopia: a randomized control trial study, 2018. *BMC Anesthesiol*. 2020 Aug 4;20(1):191. doi: 10.1186/s12871-020-01115-6.
5. Mbinze JK, Lebrun P, Debrus B, Dispas A, Kalenda N, J. Mavar TM, Schofield T, Boulanger B, Rozet E, Hubert P, Marini RD. Application of an innovative design space optimization strategy to the development of liquid chromatographic methods to combat potentially counterfeit nonsteroidal anti-inflammatory drugs, *J. Chromatogr. A*, 1263, 2012, 113–124.
6. Guillaume D, Nguyen D, Rudaz S, Veuthey JL. Method Transfer for Fast Liquid Chromatography in Pharmaceutical Analysis: Application to Short Columns Packed with Small Particle. Part I: Isocratic Separation, *Eur. J. Pharm. Biopharm*, 66, 2007, 475-482.
7. Hubert P, Nguyen-Huu JJ, Boulanger B, Chapuzet E, Cohen N, Compagnon PA, Dewé W, Feinberg M, Laurentie M, Mercier N, Muzard G, Valat L, Rozet E. Harmonization of strategies for the validation of quantitative analytical procedures: A SFSTP proposal—Part III, *J. Pharm. Biomed. Anal.*, 45, 2007, 82-96.
8. Debrus B, Lebrun P, Kindenge JM, Lecomte F, Ceccato A, Caliaro G, Mbay JM, Boulanger B, Marini RD, Rozet E, Hubert P. Innovative high-performance liquid chromatography method development for the screening of 19 antimalarial drugs based on a generic approach, using design of experiments, independent component analysis and design space, *J Chromatogr A*, 1218, 2011, 5205-5215.
9. Boulanger B, Rozet E, Moonen F, Rudaz S, Hubert P. A risk-based analysis of the AAPS conference report on quantitative bioanalytical methods validation and implementation, *J Chromatogr B Analyt Technol Biomed Life Sci.*, 877, 2009, 2235-2243.